AstraZeneca PLC (AZN)
Automate Your Wheel Strategy on AZN
With Tiblio's Option Bot, you can configure your own wheel strategy including AZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AZN
- Rev/Share 18.2813
- Book/Share 14.4548
- PB 10.1335
- Debt/Equity 0.7343
- CurrentRatio 0.8629
- ROIC 0.1089
- MktCap 453353881200.0
- FreeCF/Share 3.0844
- PFCF 47.4132
- PE 54.44
- Debt/Assets 0.2921
- DivYield 0.0211
- ROE 0.1991
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AZN | Exane BNP Paribas | -- | Outperform | -- | $75 | April 15, 2025 |
| Upgrade | AZN | UBS | Neutral | Buy | -- | -- | Feb. 13, 2025 |
| Initiation | AZN | Morgan Stanley | -- | Overweight | -- | -- | Feb. 12, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Sept. 13, 2024 |
News
Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot
Published: March 21, 2025 by: CNBC International TV
Sentiment: Positive
Pascal Soriot, CEO of British pharmaceutical giant AstraZeneca, discusses the company's $2.5 billion investment in a new China research and development center.
Read More
Watch CNBC's full interview with Pascal Soriot, AstraZeneca CEO
Published: March 21, 2025 by: CNBC International TV
Sentiment: Positive
Pascal Soriot, CEO, AstraZeneca discusses the company's $2.5 billion investment in its new China research and development centre.
Read More
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Negative
The latest trading day saw Astrazeneca (AZN) settling at $76.32, representing a -0.97% change from its previous close.
Read More
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.
Read More
AstraZeneca Stock Nears Buy Point After Long Run In Declining Market
Published: March 13, 2025 by: Investors Business Daily
Sentiment: Neutral
This biopharmaceutical stock is nearing a buy point of a cup-with-handle base. The post AstraZeneca Stock Nears Buy Point After Long Run In Declining Market appeared first on Investor's Business Daily.
Read More
AstraZeneca experimental blood pressure drug has a good shot of becoming a blockbuster
Published: March 12, 2025 by: Proactive Investors
Sentiment: Positive
UBS has reaffirmed its 'buy' rating on AstraZeneca PLC (LSE:AZN) with a 12-month price target of 14,200p, with the bank is optimistic about the potential of its blood pressure drug, baxdrostat. The Anglo-Swedish drugs giant is developing baxdrostat as part of a new class of treatments called aldosterone synthase inhibitors (ASIs).
Read More
BioInvent International AB: Year-End Report January 1 - December 31, 2024
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical programs. We now have two Phase 2 and four Phase 1 trials running in our six clinical programs leveraging the TNFR2 and FcyRIIB targets.
Read More
AstraZeneca gets £2bn boost from breast cancer drug readout
Published: February 26, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) has seen £2 billion added to its market value after reporting positive results from a breast cancer drug trial. The experimental treatment, camizestrant, improved patient survival without the disease worsening, according to an interim analysis.
Read More
AstraZeneca therapy improves survival in late-stage breast cancer trial
Published: February 26, 2025 by: Reuters
Sentiment: Positive
Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in patients with an advanced form of breast cancer without the disease getting worse in a late-stage trial.
Read More
Final Trades: Starbucks, Astrazeneca, Western Union and the IYR
Published: February 25, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
AstraZeneca PLC Investors: Please contact the Portnoy Law Firm to recover your losses. February 21, 2025 Deadline to file Lead Plaintiff Motion
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI healthcare technology and a leader in data-driven medicine, announced a new milestone in the global adoption of its groundbreaking cancer testing applications MSK-ACCESS® powered with SOPHiA DDM™ and MSK-IMPACT® powered with SOPHiA DDM™. Thirty-seven prominent institutions, including top researchers and key opinion leaders worldwide, have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit - AZN
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131420&wire=1 or contact Joseph E. Levi, Esq.
Read More
AstraZeneca PLC Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights – AZN
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AstraZeneca PLC. of Class Action Lawsuit and Upcoming Deadlines - AZN
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Levi & Korsinsky Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131175&wire=1 or contact Joseph E. Levi, Esq.
Read More
Lost Money on AstraZeneca PLC(AZN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024.
Read More
AZN Deadline: AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Levi & Korsinsky Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131097&wire=1 or contact Joseph E. Levi, Esq.
Read More
AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AZN
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131030&wire=1 or contact Joseph E. Levi, Esq.
Read More
Final Deadline for the AstraZeneca PLC Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - AZN
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Feb. 20, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of the federal securities laws. Shareholders who purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 21, 2025.
Read More
AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline
Published: February 20, 2025 by: Investopedia
Sentiment: Positive
AstraZeneca Plc (AZN) on Tuesday said it will acquire biotech company Fusion Pharmaceuticals Inc. (FUSN) for up to $2.4 billion, expanding its pipeline of treatment for advanced prostate cancer.
Read More
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit – AZN
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit - AZN
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131005&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit - AZN
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=130981&wire=1 or contact Joseph E. Levi, Esq.
Read More
FEB 21 DEADLINE: AstraZeneca PLC Is Being Sued For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 21, 2025.
Read More
FINAL AZN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AstraZeneca PLC Investors to Join the Class Action Lawsuit
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").
Read More
AstraZeneca PLC Class Action: The Gross Law Firm Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
AstraZeneca PLC Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=130722&wire=1 or contact Joseph E. Levi, Esq.
Read More
Shareholders that Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky about Pending Class Action - AZN
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=130744&wire=1 or contact Joseph E. Levi, Esq.
Read More
About AstraZeneca PLC (AZN)
- IPO Date 1993-05-12
- Website https://www.astrazeneca.com
- Industry Drug Manufacturers - General
- CEO Pascal Claude Roland Soriot
- Employees 94300